AC Immune Announces Upcoming Industry Symposium on Parkinson’s Disease and Presentation at AD/PD™ 2026
Rhea-AI Summary
AC Immune (NASDAQ: ACIU) will host an industry symposium on Parkinson’s disease and present a first-in-class TDP-43 PET-tracer at AD/PD™ 2026 in Copenhagen, March 17–21, 2026. The symposium on March 18 highlights a precision prevention approach and features data updates, scientific talks, and a Q&A session.
Oral presentation of [18F]ACI-19626 is scheduled for March 19, focusing on biomarker pathways linking amyloid, tau, and neurodegeneration. A symposium replay will be available on the company events page.
Positive
- None.
Negative
- None.
News Market Reaction – ACIU
In the Mar 5 session, ACIU declined 3.87%, reflecting a moderate negative market reaction. Argus tracked a trough of -2.2% from its starting point during tracking. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 24 | Phase 1 trial start | Positive | +7.5% | First participant dosed in Phase 1 ACI-19764 NLRP3 inhibitor trial. |
| Dec 11 | Phase 2 interim data | Positive | +15.4% | Positive interim Phase 2 VacSYn data in early Parkinson’s disease. |
| Nov 11 | Investor conference | Neutral | +1.2% | Participation and fireside chat at Jefferies 2025 London conference. |
| Nov 04 | Earnings and update | Neutral | +3.8% | Q3 2025 results, cash runway to Q3 2027, and narrowed R&D focus. |
| Oct 28 | Advisory appointment | Positive | -1.9% | Appointment of Prof. Catherine Mummery as Clinical Advisory Board Chair. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent substantive R&D and clinical updates have generally aligned with positive price reactions, with only one notable divergence on a management appointment.
Over the past six months, AC Immune has highlighted several pipeline and corporate milestones. Positive interim Phase 2 VacSYn data for Parkinson’s disease and a new Phase 1 NLRP3 trial both saw share gains of 15.41% and 7.51%, respectively. Q3 2025 results emphasized CHF 108.5M in cash and funding into Q3 2027. A Jefferies conference appearance had a modest positive reaction, while the appointment of Catherine Mummery to chair the Clinical Advisory Board saw a small negative move despite its strategic significance.
Key Terms
phase 2 medical
pet-tracer medical
tdp-43 medical
biomarker medical
α-synuclein medical
active immunotherapy medical
form 144 regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
AC Immune Announces Upcoming Industry Symposium on Parkinson’s Disease and Presentation at AD/PD™ 2026
- AC Immune to host symposium highlighting Precision Prevention approach to Parkinson's disease
- Presentation at International Conference on Alzheimer’s and Parkinson’s Disease (AD/PD™ 2026) showcases potential of first-in-class TDP-43 PET-tracer ACI-19626
Lausanne, Switzerland, March 5, 2026 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced it will host an industry symposium on how a precision prevention approach to Parkinson’s disease may now be within reach, based on lessons from Alzheimer’s disease.
AC Immune will also present its first-in-class TDP-43 PET-tracer on ACI-19626 at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2026) taking place in Copenhagen, Denmark, on March 17-21, 2026.
Industry Symposium: From Treatment to Prevention in Parkinson’s Disease
Session Date/Time: Wednesday, March 18, 2026, 8:40 – 10:40 am CET
Location: Hall A1
- Opening and Closing Remarks: Andrea Pfeifer, Ph.D., CEO of AC Immune
- Shifting treatment to prevention: lessons learned from Alzheimer’s disease
Presenter: Prof. Catherine Mummery (University College London)
Time: 8:45 – 9:00 am CET
- Targeting α-synuclein in Parkinson’s disease: pathophysiology and supporting evidence
Presenter: Werner Poewe, M.D. (Medical University of Innsbruck)
Time: 9:00 – 9:25 am CET
- Misfolding of α-synuclein as fluid biomarker measured with the iRS platform of betaSENSE
Presenter: Prof. Klaus Gerwert (Centre for Protein Diagnostics at Ruhr University Bochum)
Time: 9:25 – 9:40 am CET
- Stabilizing the progression of Parkinson’s disease with active immunotherapy: Interim results of the Phase 2 VacSYn trial of ACI-7104.056
Presenter: Günther Staffler, Ph.D. (AC Immune)
Time: 9:40 – 10:05 am CET
- Intracellular targeting of α-synuclein with Morphomer small molecules
Presenter: Francesca Capotosti, Ph.D. (AC Immune)
Time: 10:05 – 10:20 am CET
The presentations will be followed by a Q&A session, and a replay of the Industry Symposium will be available on the Events page of AC Immune’s website after the event.
Oral Presentation
- Discovery and initial clinical evaluation of [18f]ACI-19626, a first-in-class TDP-43 PET-tracer
Presenter: Tamara Seredenina, Ph.D. (AC Immune)
Session: Biomarker Pathways Linking Amyloid, Tau, and Neurodegeneration
Location: Hall 180-181
Date/Time: Thursday, March 19, 2026 at 4:50 – 5:05 pm CET
About AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company and a global leader in precision prevention for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and NeuroOrphan indications driven by misfolded proteins. The Company’s two clinically validated technology platforms, SupraAntigen® and Morphomer®, fuel its pipeline of first- and best-in-class assets, which currently features a range of therapeutic and diagnostic programs, including candidates in Phase 2 and Phase 3 development. AC Immune has a strong track record of securing strategic partnerships with leading global pharmaceutical companies, resulting in substantial non-dilutive funding to advance its proprietary programs and >
SupraAntigen® is a registered trademark of AC Immune SA in the following territories: AU, EU, CH, GB, JP, RU, SG and USA. Morphomer® is a registered trademark of AC Immune SA in CA, CN, CH, EU, GB, JP, KR, NO, RU and SG.
The information on our website and any other websites referenced herein is expressly not incorporated by reference into, and does not constitute a part of, this press release.
For further information, please contact:
| SVP, Investor Relations & Corporate Communications Gary Waanders, Ph.D., MBA AC Immune Phone: +41 21 345 91 91 Email: gary.waanders@acimmune.com | |
| International Media Chris Maggos Cohesion Bureau Phone: +41 79 367 6254 Email: chris.maggos@cohesionbureau.com |
Forward looking statements
This press release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “outlook” or “continue,” and other comparable terminology. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions “Item 3. Key Information – Risk Factors” and “Item 5. Operating and Financial Review and Prospects” in AC Immune’s Annual Report on Form 20-F and other filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.
Attachment
